Genscript Biotech Corporation provided earnings guidance for the year ended 31 December 2021. For the period, the Group is expected to record a loss of approximately $466.9 million to $518.6 million for the year ended 31 December 2021, as compared to a loss of approximately $281.4 million in 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.02 HKD | -0.66% | +3.26% | -39.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.48% | 3.29B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- 1548 Stock
- News Genscript Biotech Corporation
- Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021